Imugene Posts Encouraging Early Results for Azer-cel Therapy
Imugene Limited (ASX: IMU) has reported positive early findings from its ongoing Phase 1b clinical trial evaluating azer-cel, an off-the-shelf CAR T-cell therapy targeting blood cancers. The study focused on patients with relapsed or treatment-resistant cancers who had not previously undergone CAR T therapy.
The therapy demonstrated strong activity across multiple cancer types. Out of 16 evaluable patients, the overall response rate reached 81%. Marginal zone lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and Waldenström macroglobulinemia each recorded a 100% response rate, while diffuse large B-cell lymphoma achieved a 60% response rate.
The trial also showed favourable safety outcomes and strong CAR T-cell expansion, supporting the treatment’s potential as a scalable cancer therapy platform. Imugene believes the latest results strengthen the commercial and clinical outlook for azer-cel and may support broader development opportunities across several hematological cancer indications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imugene Posts Encouraging Early Results for Azer-cel Therapy
Imugene Limited (ASX: IMU) has reported positive early findings from its ongoing Phase 1b clinical trial evaluating azer-cel, an off-the-shelf CAR T-cell therapy targeting blood cancers. The study focused on patients with relapsed or treatment-resistant cancers who had not previously undergone CAR T therapy.
The therapy demonstrated strong activity across multiple cancer types. Out of 16 evaluable patients, the overall response rate reached 81%. Marginal zone lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and Waldenström macroglobulinemia each recorded a 100% response rate, while diffuse large B-cell lymphoma achieved a 60% response rate.
The trial also showed favourable safety outcomes and strong CAR T-cell expansion, supporting the treatment’s potential as a scalable cancer therapy platform. Imugene believes the latest results strengthen the commercial and clinical outlook for azer-cel and may support broader development opportunities across several hematological cancer indications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au